Taking an indepth look at Programs, Clinical Trials, Cores, and More!

If you're having trouble viewing this email, you may see it online. Share this email:

Feature Story Cancer Cell Biology Program: Bridging the Gap Between Benchwork and Bedside The “omics” revolution is expanding exponentially. On the heels of the omics era, new paradigms are needed to harness and translate basic science advances to clinical applications... [Read More] Spotlight Trial A Phase II Study Examines the Potential of Immune Checkpoint Inhibitor Combination Therapies for Patients with Oncogene-Driven Lung Cancer A phase II trial open at Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital under principal investigator Alice Shaw, MD, PhD (MGH), draws on recent advances in immunotherapy... [Read More] A Phase II Study of Nivolumab Combined with Ipilimumab for Patients with Advanced Rare Genitourinary Tumors A trial is now enrolling at two DF/HCC member institutions, led by Bradley A McGregor, MD (DFCI), that will evaluate combination therapy... [Read More] More on Cores Collaborative Functional Genomics Core Facility In this DF/HCC eNews Spotlight Edition, we present the DF/HCC Collaborative Functional Genomics Core, which provides a single portal through which DF/HCC members can learn about RNAi and CRISPR-Cas9 screen services relevant to mouse, human, and Drosophila... [Read More] Publications Mixtape Here is a selection of recent collaborative publications involving DF/HCC authors for your reading pleasure. Click here to browse the "Mixtape". New Faces Leadership Since our last edition of eNews there have been eleven leadership changes at the Cancer Center, Program, and Core levels. Learn more about our new leaders. Members Join us in welcoming the 12 individuals from our member institutions who have recently joined DF/HCC. Learn more about these scientists and their research interests, and watch the intro videos that they have recorded. Awards Congratulations to the DF/HCC faculty who have been recognized for their outstanding research contributions since our last edition of eNews! Learn more about who was honored. Recently Awarded NIH Grants The NIH continues to recognize DF/HCC as a leader in cancer research by awarding funding to a number of our research initiatives. Learn more about these funded projects. Research Highlights from Our Member Institutions Beth Israel Deaconess Medical Center Flipping the Switch: Dietary fat, changes in fat metabolism may promote prostate cancer metastasis Boston Children's Hospital Why Evolution is the challenge - and the promise - in developing a vaccine against HIV Brigham and Women's Hospital  Removing Cancer Cell Debris Improves Conventional Cancer Treatments Dana-Farber Cancer Institute Patients and researchers team up to fight metastatic prostate cancer Harvard Medical School Hidden Variation - Study reveals startlingly different tissue sensitivities to cancer-driving genes Harvard T.H. Chan School of Public Health Breakthrough brings targeted drug delivery within ARMM’s reach Massachusetts General Hospital New Genetic-Based Treatment for Glioneuronal Tumors In This Issue Spotlight Trial More on Cores Publication Playlist New Faces Awards Funding Did you know? We've added a couple new features to our website! Visit the DF/HCC Experimental Therapeutics Clinical Trials Network Page Visit the Templates and Branding page Our Member Institutions: Beth Israel Deaconess Medical Center  Brigham and Women's Hospital  Boston Children's Hospital Dana-Farber Cancer Institute Harvard Medical School Harvard T.H. Chan School of Public Health Massachusetts General Hospital www.dfhcc.harvard.edu dfhcc@partners.org Dana-Farber/Harvard Cancer Center Central Administration 10 Brookline Place, BP339B Brookline, MA 02445

Manage your preferences | Opt out using TrueRemove® Got this as a forward? Sign up to receive our future emails. 450 Brookline Avenue Boston , MA | 02215 US This email was sent to . To continue receiving our emails, add us to your address book.

Subscribe to our email list.